# MZE782 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mze782

> The next catalyst for MZE782, sponsored by Maze Therapeutics, Inc. (MAZE), is its interim data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for MZE782?

The next catalyst for MZE782, sponsored by Maze Therapeutics, Inc. (MAZE), is its interim data readout, 2027. Press release filed with the SEC (EX-99): ""The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with initial topline data expected in 2027, and continued strong enrollment in the Phase 2 HORIZON trial of MZE829 across three cohorts with additional data on track for 10-15 patients per cohort in late 2026 or early 2027," said Jason Coloma, Ph.D., chief executive officer of Maze." [Calendar and source filings](https://sec-api.dev/pdufa/mze782)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-344878, https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-08-11. Cite: https://sec-api.dev/pdufa/mze782#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | MZE782 |
| Codes | MZE782 |
| Sponsor | Maze Therapeutics, Inc. (MAZE) https://sec-api.dev/companies/maze/catalysts |
| Indications | phenylketonuria, or pku, pku in 2027, pku and in patients with ckd in 2026, pku and patients with ckd, pku in mid-2026, [Phenylketonuria (PKU)](https://sec-api.dev/indications/phenylketonuria-pku) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-01-31, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-047207): "In September 2024, Maze initiated a Phase 1 clinical trial of MZE782 in healthy volunteers." https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-453619): "We initiated a Phase 1 clinical trial of our second lead program, MZE782, in September 2024 and announced initial clinical data in healthy adult volunteers in September 2025." https://www.sec.gov/Archives/edgar/data/1842295/000119312526453619/maze-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-344903): "We initiated a Phase 1 clinical trial of our second lead program, MZE782, in September 2024 and announced initial clinical data in healthy adult volunteers in September 2025." https://www.sec.gov/Archives/edgar/data/1842295/000119312526344903/maze-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-219430): "We initiated a Phase 1 clinical trial of our second lead program, MZE782, in September 2024 and announced initial clinical data in phenylketonuria, or PKU, and chronic kidney disease, or CKD, in September 2025." https://www.sec.gov/Archives/edgar/data/1842295/000119312526219430/maze-20260331.htm
- SEC Form 10-K (accession 0001193125-26-122778): "We initiated a Phase 1 clinical trial of our second lead program, MZE782, in September 2024 and announced initial clinical data in phenylketonuria, or PKU, and chronic kidney disease, or CKD, in September 2025." https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/maze-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-269689): "We initiated a Phase 1 clinical trial of our second lead program, MZE782, in September 2024 and announced results from the Phase 1 clinical trial in September 2025." https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-107306): "We initiated a Phase 1 clinical trial of our second lead program, MZE782, in September 2024." https://www.sec.gov/Archives/edgar/data/1842295/000095017025107306/maze-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-071375): "We initiated a Phase 1 clinical trial of our second lead program, MZE782, in September 2024." https://www.sec.gov/Archives/edgar/data/1842295/000095017025071375/maze-20250331.htm
- SEC Form 10-K (accession 0000950170-25-047208): "We initiated our Phase 1 trial of MZE782 in September 2024 and expect to provide initial data from this trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000095017025047208/maze-10k-2024.htm
- SEC Form 10-K (accession 0000950170-25-047208): "In September 2024, we initiated a Phase 1 clinical trial evaluating MZE782 in healthy volunteers." https://www.sec.gov/Archives/edgar/data/1842295/000095017025047208/maze-10k-2024.htm
- SEC Form 10-K (accession 0000950170-25-047208): "We initiated a Phase 1 clinical trial of our second lead program, MZE782, in September 2024." https://www.sec.gov/Archives/edgar/data/1842295/000095017025047208/maze-10k-2024.htm
- SEC prospectus (424B) (accession 0001193125-25-018482): "We initiated our Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000119312525018482/d769642d424b4.htm

### Q3 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-01-31, last confirmed 2025-08-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107299): "Maze expects to report initial data, including biomarker and proof-of-mechanism results relevant for both indications, in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-071357): "Maze expects to report initial data, including proof-of-mechanism biomarker results, in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000095017025071357/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-047207): "Maze expects to report initial data, including proof-of-mechanism biomarkers, in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-071357): "MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025" https://www.sec.gov/Archives/edgar/data/1842295/000095017025071357/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-047207): "MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025" https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-ex99_1.htm
- SEC Form 10-K (accession 0000950170-25-047208): "We initiated a Phase 1 clinical trial of MZE782 in September 2024 and expect to provide initial data from this trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000095017025047208/maze-10k-2024.htm
- SEC Form 10-K (accession 0000950170-25-047208): "We initiated our Phase 1 trial of MZE782 in September 2024 and expect to provide initial data from this trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000095017025047208/maze-10k-2024.htm
- SEC Form 10-K (accession 0000950170-25-047208): "We initiated a Phase 1 trial of MZE782 in September 2024 and expect to provide initial data from this trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000095017025047208/maze-10k-2024.htm
- SEC prospectus (424B) (accession 0001193125-25-018482): "Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000119312525018482/d769642d424b4.htm
- SEC prospectus (424B) (accession 0001193125-25-018482): "We initiated our Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000119312525018482/d769642d424b4.htm
- SEC prospectus (424B) (accession 0001193125-25-018482): "We initiated a Phase 1 clinical trial of MZE782 in September 2024 and expect to provide initial data from this trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000119312525018482/d769642d424b4.htm
- SEC prospectus (424B) (accession 0001193125-25-018482): "We initiated a Phase 1 trial of MZE782 in September 2024 and expect to provide initial data from this trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1842295/000119312525018482/d769642d424b4.htm

### 2H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-03-31, last confirmed 2025-03-31.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-047207): ""We look forward to reporting initial Phase 1 data for MZE782 in healthy volunteers in the second half of 2025, which will enable us to prepare to initiate Phase 2 trials in CKD and PKU." https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-ex99_1.htm

### mid-2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2. Indication: PKU and patients with CKD.
- First seen 2025-08-12, last confirmed 2026-05-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219398): "Maze plans to initiate two Phase 2 proof-of-concept trials of MZE782 evaluating plasma phenylalanine (Phe) reduction in PKU and proteinuria reduction in CKD by mid-2026 and in the second half of 2026, respectively." https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-122774): "Maze plans to initiate two Phase 2 proof-of-concept trials of MZE782 evaluating plasma phenylalanine (Phe) reduction in PKU and proteinuria reduction in CKD by mid-2026 and in the second half of 2026, respectively." https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-269624): "Maze plans to initiate two Phase 2 proof-of-concept trials of MZE782, evaluating plasma Phe reduction in PKU and proteinuria reduction in CKD, in 2026." https://www.sec.gov/Archives/edgar/data/1842295/000119312525269624/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-200760): "Maze plans to initiate two Phase 2 proof-of-concept trials of MZE782, evaluating plasma Phe reduction in PKU and proteinuria reduction in CKD in 2026." https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/d90404dex992.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-107299): "Based on Phase 1 results, Maze plans to initiate two separate Phase 2 clinical trials of MZE782 in CKD and PKU in 2026." https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/maze-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-219430): "We plan to initiate Phase 2 proof-of-concept trials of MZE782 in patients with PKU by mid-2026 and in patients with CKD in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1842295/000119312526219430/maze-20260331.htm
- SEC prospectus (424B) (accession 0001193125-26-170687): "We plan to initiate Phase 2 proof-of-concept trials of MZE782 in PKU by mid-2026 and in CKD in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1842295/000119312526170687/d15217d424b5.htm
- SEC Form 10-K (accession 0001193125-26-122778): "Based on these results, we plan to initiate a Phase 2 proof-of-concept trial of MZE782 evaluating plasma Phe reduction in patients with PKU in mid-2026." https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/maze-20251231.htm
- SEC Form 10-K (accession 0001193125-26-122778): "We plan to initiate a Phase 2 proof-of-concept trial of MZE782 in CKD in the second half of 2026" https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/maze-20251231.htm
- SEC Form 10-Q (accession 0001193125-26-219430): "We plan to initiate two Phase 2 trials of MZE782 in PKU and CKD in 2026." https://www.sec.gov/Archives/edgar/data/1842295/000119312526219430/maze-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-219430): "We plan to initiate two Phase 2 trials of MZE782 in patients with PKU and in patients with CKD in 2026." https://www.sec.gov/Archives/edgar/data/1842295/000119312526219430/maze-20260331.htm
- SEC Form 10-K (accession 0001193125-26-122778): "We plan to initiate two Phase 2 proof-of-concept trials of MZE782 in 2026 in patients with PKU and patients with CKD." https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/maze-20251231.htm

### 2027: interim data readout

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2026-08-11, last confirmed 2026-08-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-344878): ""The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with initial topline data expected in 2027, and continued strong enrollment in the Phase 2 HORIZON trial of MZE829 across three cohorts with additional data on track for 10-15 patients per cohort in late 2026 or early 2027," said Jason Coloma, Ph.D., chief executive officer of Maze." https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-ex99_1.htm

### 1H 2027: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-08-11, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-453590): "We are also making strong progress with MZE782 with respect to both continued enrollment in the Phase 2 CIPheR trial in PKU and advancement of our plans to initiate a Phase 2 CKD trial in the first half of 2027."" https://www.sec.gov/Archives/edgar/data/1842295/000119312526453590/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-453590): "Maze plans to initiate a Phase 2 proof-of-concept trial of MZE782 evaluating proteinuria reduction in CKD in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526453590/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-344878): "Maze plans to initiate a Phase 2 proof-of-concept trial of MZE782 evaluating proteinuria reduction in CKD in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-453619): "We plan to initiate a Phase 2 proof-of-concept trial of MZE782 in patients with CKD in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526453619/maze-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-344903): "We plan to initiate a Phase 2 proof-of-concept trial of MZE782 in patients with CKD in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526344903/maze-20260630.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Phenylketonuria (PKU).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07694440 (A Study of MZE782 in Adults With PKU): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Maze Therapeutics." https://clinicaltrials.gov/study/NCT07694440

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Phenylketonuria (PKU).
- First seen 2026-04-22, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07694440 (A Study of MZE782 in Adults With PKU): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Maze Therapeutics." https://clinicaltrials.gov/study/NCT07694440
- Press release filed with the SEC (EX-99) (accession 0001193125-26-453590): "Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027" https://www.sec.gov/Archives/edgar/data/1842295/000119312526453590/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-344878): "Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027" https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219398): ""Looking ahead to the rest of the year, we remain on track to initiate a Phase 2 trial of MZE782 in PKU around the middle of this year with topline data expected in 2027, and an additional Phase 2 study is expected to initiate in CKD in the second half of this year." https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/maze-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-453619): "In August 2026, we announced that the Phase 2 proof-of-concept trial of MZE782 in patients with PKU has initiated and we anticipate reporting topline data from this trial in 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526453619/maze-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-453619): "In August 2026, we announced that the Phase 2 proof-of-concept trial of MZE782 in patients with phenylketonuria, or PKU, has initiated and we anticipate reporting topline data from this trial in 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526453619/maze-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-344903): "In August 2026, we announced that the Phase 2 proof-of-concept trial of MZE782 in patients with PKU has initiated and we anticipate reporting topline data from this trial in 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526344903/maze-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-344903): "In August 2026, we announced that the Phase 2 proof-of-concept trial of MZE782 in patients with phenylketonuria, or PKU, has initiated and we anticipate reporting topline data from this trial in 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526344903/maze-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-219430): "We anticipate reporting topline data from the Phase 2 trial of MZE782 in patients with PKU in 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526219430/maze-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219398): "Topline data from the PKU Phase 2 trial is expected in 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/maze-ex99_1.htm
- SEC prospectus (424B) (accession 0001193125-26-170687): "We anticipate reporting topline data for the Phase 2 trial for PKU in 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526170687/d15217d424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-453590): "Topline data from the trial is expected in 2027." https://www.sec.gov/Archives/edgar/data/1842295/000119312526453590/maze-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mze782.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MZE782 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mze782

```bibtex
@misc{secapidev_pdufa_mze782_20261116,
  title        = {MZE782 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mze782}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mze782_20261116","title":"MZE782 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mze782","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
